Disclosed is a method and apparatus for more locally stimulating a desired stimulation region in a predetermined part of an object, the apparatus including a first ultrasonic wave generator configured to output a first ultrasonic beam to a predetermined part of an object, a second ultrasonic wave generator configured to output a second ultrasonic beam to the predetermined part of the object, and a controller configured to control the first ultrasonic wave generator and the second ultrasonic wave generator such that central axes of the first ultrasonic wave generator and the second ultrasonic wave generator are disposed on the same plane, and a crossing angle between the first ultrasonic beam and the second ultrasonic beam is a predetermined angle.

A neuromodulation catheter includes an elongate shaft and a neuromodulation element. The shaft includes two or more first cut shapes and two or more second cut shapes along a helical path extending around a longitudinal axis of the shaft. The first cut shapes are configured to at least partially resist deformation in response to longitudinal compression and tension on the shaft and torsion on the shaft in a first circumferential direction. The second cut shapes are configured to at least partially resist deformation in response to longitudinal compression on the shaft and torsion on the shaft in both first and second opposite circumferential directions.

Embodiments of the present disclosure relate to techniques for inducing physiological perturbations in a subject via neuromodulation, e.g., peripheral neuromodulation of a region of interest of an organ. The nature and degree of the perturbations may be related to the subject's clinical condition. Accordingly, an assessment of one or more characteristics of the perturbations may be used to determine a clinical condition of the subject.

Methods for treating a human patient having a subarachnoid hematoma, such as to prevent cerebral vasospasm or to reduce the severity of cerebral vasospasm in the patient, and associated devices, systems, and methods are disclosed herein. In a particular embodiment, a thrombolytic agent is introduced extravascularly into a subarachnoid region including the hematoma. A headset configured for hands-free delivery of transcranial ultrasound energy is connected to the patient and used to deliver ultrasound energy to the subarachnoid region to enhance the thrombolytic effect of the thrombolytic agent. The type and/or dosage of the thrombolytic agent can be selected based on the enhanced thrombolytic effect. For example, the enhanced thrombolytic effect can allow the therapeutically effective use of less aggressive thrombolytic agents and/or lower dosages of thrombolytic agents. In some cases, this can reduce the clinical probability of additional cerebral hemorrhage.

The present invention relates to a method for transiently disrupting a region of the blood-brain barrier (BBB) of a human using ultrasounds in the presence of an ultrasound contrast agent, and uses thereof. The method comprises the application of at least one ultrasound (US) beam with a pressure level higher than 1 MPa and a resonance frequency ranging from 0.5 to 1.5 MHz.

An ultrasound system for use in unbinding an active agent from a plasma protein in a target site in a subject includes a transducer configured to generate acoustic pressure waves and a controller coupled to the transducer. The controller is programmed to control the transducer to produce a plurality of pulsed acoustic pressure waves in the target site of the patient. The plurality of pulsed acoustic pressure waves disrupt a plasma protein binding between the active agent and the plasma protein within the target site. The disruption of the plasma protein binding causes an increase in an amount of unbound active agent in the target site.

The invention relates to medical therapy of detrimental lesions. A system treats with non-invasive arrays of non-ionizing energy-radiation sources. The external sources focus energy dose distribution to a selected volume in a body. Energy output is directed towards a pathologic location and quenched around other sites or healthy tissue. Beam aiming is done without source movement. Targeted, volumetrically discrete energy deposition can beneficially manipulate lesions within the body. The purpose of the focused and enhanced energy deposition is to repair or disable pathologic physiology or structures, nerve pathways, extracellular fluid, and misfolded proteins. Locally augmented energy is used to enhance immunity, release pharmaceutical compounds from energy-sensitive vesicles and reconfigure or eliminate misfolded proteins and their aggregates. Targeted tissue may have enhanced sensitivity to received energy via a non-ionizing-radiation, treatment-localizing agent. This system optimizes delivery of non-ionizing, non-ablating electromagnetic or mechanical energy, degrading or repairing an abnormality upon interaction with it.

A system comprises an ultrasound subsystem and a magnetic resonance imaging (MRI) subsystem. The ultrasound subsystem applies pulses of focused ultrasound having one or more parameters to an identified location in a subject that is to receive treatment. The parameters are determined in accordance with a magnetic resonance guided focused ultrasound (MRgFUS) treatment plan. The MRI subsystem acquires functional image data corresponding to the identified location concurrently with the applied pulses of focused ultrasound. The MRI subsystem obtains a reconstructed series of functional images of the subject using the functional image data. The functional images are indicative of a first region within the identified location in which neuronal activity has been modified by the applied pulses. The system is configured to adjust one or more parameters of the MRgFUS treatment plan using the reconstructed series of functional images.

The present disclosure relates to a pair of intelligent glasses and a glasses box. The intelligent glasses can include a frame assembly having an inner frame portion and an outer frame portion that is arranged around the inner frame portion, a detection component configured to detect physiological characteristics of a wearer, a control component connected with the detection component and configured to acquire a control signal generated according to the physiological characteristics and a treatment component, connected with the control component and configured to output treatment signals according to the control signal. One or more accommodating spaces are formed between the inner frame portion and the outer frame portion. The treatment signals include at least one of a phototherapy signal, a sonic wave signal, a sound wave signal, magnetic waves, or electromagnetic waves. The detection component, the control component and the treatment component are located in the accommodating spaces.

The present specification discloses a neuromodulation system comprising a transcranially mounted neuromodulation device and a stimulation control computing environment. The disclosed neuromodulation device comprising at least one ultrasound transducer and at least one EEG electrode and the disclosed stimulation control computing environment comprises a stimulation control unit and offline computing device, the disclosed stimulation control unit including associated systems and methods for controlling the neuromodulation device functionality using acoustic simulations performed on brain image data as well as methods and uses of such neuromodulation systems in modulating brain activity using focused ultrasound stimulation of the thalamus and thalamic sub regions during certain phases of slow wave brain oscillations in order to treat various neural-based disorders or conditions including sleep disorders.